AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00992121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib 3 week
Description: Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.
Study NCT04582513 — intervention group
Intervention type: OTHER
Intervention: AnCHor-Checklist implementation
Description: a standardized checklist using the SBAR concept according to the recommendations of the DGAI
Study NCT04317001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Treatment will be with 100mg of modafinil for the two week primary phase of the study
Study NCT04317001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02877264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vapendavir 132 mg capsule
Study NCT02877264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vapendavir 264 mg tablet
Study NCT02877264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vapendavir 24 mg/mL oral suspension
Study NCT01476124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine Placebo
Description: Morphine Placebo
Study NCT01476124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Description: Gabapentin enacarbil 600 mg
Study NCT01476124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine extended release 60 mg
Study NCT01476124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn Placebo
Description: Gabapentin enacarbil placebo
Study NCT01860547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberries
Description: Frozen bilberries, 100 g/d
Study NCT01860547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn berry
Description: Dried sea buckthorn berries, 20 g/d
Study NCT01860547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn phenolic extract
Description: Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
Study NCT01860547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil
Description: Sea buckthorn oil, 4 g (8 capsules)/d
Study NCT03398421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib
Description: Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
Study NCT03398421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be given as 100 mg per capsule per day administered orally with water
Study NCT03990298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Awake endoscopy
Description: Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
Study NCT02412111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02412111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivacaftor
Study NCT02412111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Study NCT00788164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-HPV
Description: Given intramuscularly
Study NCT00788164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: Given intramuscularly
Study NCT00788164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Given topically
Study NCT05061069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cervical vestibular evoked myogenic potentials (cVEMP)
Description: cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
Study NCT03494855 — intervention group
Intervention type: DEVICE
Intervention: SyMRI Software
Description: The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
Study NCT03240497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Exposure
Description: The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\].
Study NCT03240497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Ventilation
Description: The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
Study NCT02939976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-vessel Disease, Complete Revascularization
Description: Complete revascularization of all diseased arteries
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Resolute family of stents
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Resolute family of stents
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology
Description: Complete revascularization of all diseased arteries
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo Glidesheath Slender
Description: Possible use of Terumo Glidesheath Slender
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo Glidesheath Slender
Description: Possible use of Terumo Glidesheath Slender
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo TR Band Radial Compression Device
Description: Possible use of Terumo TR Band Radial Compression Device
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo TR Band Radial Compression Device
Description: Possible use of Terumo TR Band Radial Compression Device
Study NCT02539654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%
Study NCT02539654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Study NCT03557476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Octacosanol
Description: One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
Study NCT03557476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
Study NCT02325245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
Study NCT02325245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
Study NCT02589353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Lenacapavir Placebo
Description: Tablets administered without regard to food
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Failing ARV Regimen
Description: Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Failing ARV Regimen
Description: Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: Optimized background regimen as prescribed by the Investigator
Study NCT04593706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone acetate + Betamethasone sodium phosphate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study NCT04593706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study NCT04150068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optimized Background Regimen (OBR)
Description: Optimized background regimen as prescribed by the Investigator
Study NCT01007292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: intravenous infusion
Study NCT01007292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: intravenous infusion
Study NCT02839876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Description: Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
Study NCT02839876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen
Description: Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
Study NCT00312572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch applied for 7-day wear.
Study NCT04222140 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERIPTO Protocol
Description: combination biologic treatment
Study NCT04222140 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BMAC Only
Description: BMAC treatment only
Study NCT03362580 — intervention group
Intervention type: DEVICE
Intervention: Slit lamp examination
Description: The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
Study NCT03362580 — intervention group
Intervention type: DEVICE
Intervention: Undilated 7-field color fundus photography
Description: Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
Study NCT03362580 — intervention group
Intervention type: DEVICE
Intervention: Color scan
Description: Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
Study NCT03362580 — intervention group
Intervention type: DEVICE
Intervention: Spectral domain optical coherence tomography
Description: Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
Study NCT03027323 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AxoTrack System
Description: The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
Study NCT03345628 — intervention group
Intervention type: DRUG
Intervention: Sedatives
Description: sedated group received sedative drugs to tolerated intubation and ventilation
Study NCT00715845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Description: For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
Study NCT02918643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients
Study NCT02918643 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients
Study NCT03976414 — intervention group
Intervention type: OTHER
Intervention: eMOM
Description: The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
Study NCT00964015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Hydroxyethyl Starch 130/0.4
Study NCT00964015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Study NCT03453112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster 100/6mg NEXThaler
Description: Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
Study NCT03453112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster 100/6mg pMDI
Description: Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA_134a propellant
Study NCT01178814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (Lenalidomide)
Description: The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
Study NCT02003456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82
Description: Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
Study NCT02716766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: PO
Study NCT02716766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: PO
Study NCT02716766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO
Study NCT02716766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV
Study NCT01752634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab (AIN457)
Description: Secukinumab (AIN457)
Study NCT01752634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab (AIN457)
Study NCT01752634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PFS for s.c. administration.
Study NCT00957905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV
Study NCT00957905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00957905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00957905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01294748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent DES
Description: The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
Study NCT01294748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor DES
Description: The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
Study NCT01048905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine
Description: Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
Study NCT00898326 — intervention group
Intervention type: OTHER
Intervention: biopsy
Description: Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
Study NCT03570008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 9 days spa residential program
Description: After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts.